Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim in Thrombocytopenic Low/Int-1 Risk MDS
NCT00303472Phase 2Completed
- Sponsor
- Amgen
- Start
- Feb 2006
- Primary completion
- May 2008
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of romiplostim in myelodysplastic syndrome (MDS), sponsored by Amgen. Started Feb 2006; status: completed.
02
Drugs
romiplostim
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00303472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303472.